Frontiers in Immunology (Mar 2021)
Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China
- Wei Cao,
- Xiaosheng Liu,
- Xiaosheng Liu,
- Xiaosheng Liu,
- Ke Hong,
- Zhiyong Ma,
- Yuelun Zhang,
- Ling Lin,
- Yang Han,
- Yong Xiong,
- Zhengyin Liu,
- Lianguo Ruan,
- Taisheng Li,
- Taisheng Li,
- Taisheng Li
Affiliations
- Wei Cao
- Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Xiaosheng Liu
- Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Xiaosheng Liu
- Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
- Xiaosheng Liu
- Tsinghua-Peking Center for Life Sciences, Beijing, China
- Ke Hong
- Department of Infectious Diseases, JinYin-tan Hospital, Wuhan, China
- Zhiyong Ma
- Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China
- Yuelun Zhang
- Medial Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Ling Lin
- Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Yang Han
- Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Yong Xiong
- Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China
- Zhengyin Liu
- Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Lianguo Ruan
- Department of Infectious Diseases, JinYin-tan Hospital, Wuhan, China
- Taisheng Li
- Department of Infectious Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
- Taisheng Li
- Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
- Taisheng Li
- Tsinghua-Peking Center for Life Sciences, Beijing, China
- DOI
- https://doi.org/10.3389/fimmu.2021.671443
- Journal volume & issue
-
Vol. 12
Abstract
No abstracts available.Keywords
- COVID-19
- high-dose intravenous immunoglobulin
- immunomodulation
- 28-day mortality
- inflammatory markers
